What is Gliknik?
Gliknik is a specialized biotechnology enterprise dedicated to the discovery and development of novel biologics designed to address the underlying mechanisms of immune disorders. The company's research focus centers on the modulation of the immune system, providing a sophisticated approach to treating autoimmune diseases and various forms of cancer. By leveraging a team of expert scientists and a global network of collaborators, Gliknik is actively advancing candidates such as GL-2045 and GL-0719.
The company's market position is defined by its commitment to addressing high-unmet-need conditions, including immune thrombocytopenia and Cold Agglutinin Disease. Through its strategic focus on immune system regulation, Gliknik aims to deliver transformative treatment options that improve patient outcomes in challenging therapeutic areas.
How much funding has Gliknik raised?
Gliknik has raised a total of $52M across 11 funding rounds:
Series A
$2.9M
Unspecified
$2.4M
Unspecified
$849K
Unspecified
$3.5M
Unspecified
$2M
Private Equity
$9.9M
Series B
$4.9M
Unspecified
$2.8M
Debt
$148K
Series C
$11.5M
Debt
$11M
Series A (2008): $2.9M, investors not publicly disclosed
Unspecified (2010): $2.4M, investors not publicly disclosed
Unspecified (2010): $849K, investors not publicly disclosed
Unspecified (2011): $3.5M, investors not publicly disclosed
Unspecified (2011): $2M, investors not publicly disclosed
Private Equity (2012): $9.9M, investors not publicly disclosed
Series B (2012): $4.9M led by Baxter International
Unspecified (2013): $2.8M, investors not publicly disclosed
Debt (2021): $148K featuring PPP
Series C (2021): $11.5M backed by SAISO Partners and First In Ventures
Debt (2025): $11M, investors not publicly disclosed
Key Investors in Gliknik
Baxter International
Baxter International is a global healthcare company that develops and manufactures medical devices, pharmaceuticals, and hospital care products, including injectable therapies and surgical technologies.
SAISO Partners
An investment firm focused on providing growth capital to companies within the life sciences and biotechnology sectors.
First In Ventures
A venture capital firm specializing in early-to-growth stage investments, often targeting high-potential companies in the healthcare and technology industries.
What's next for Gliknik?
With the recent influx of capital, Gliknik is well-positioned to accelerate its clinical development programs and expand its research capabilities. The strategic roadmap likely involves advancing its lead drug candidates through critical trial phases, thereby increasing the company's valuation and potential for future commercialization. The firm's ability to attract diverse investment sources, ranging from venture capital to strategic corporate partners, provides a robust foundation for sustained growth.
Looking ahead, the company will likely prioritize the optimization of its drug discovery platform and the strengthening of its intellectual property portfolio. By focusing on high-impact therapeutic targets, Gliknik is poised to remain at the forefront of the biologics industry, potentially attracting further interest from major pharmaceutical entities seeking to bolster their own pipelines with innovative immune-modulating technologies.
